Why the study?
Inflammatory biomarkers are used to monitor cardiovascular disease progression and recurrent adverse event risk, prompting exploration of whether HMG-CoA reductase inhibitors exert a positive effect on these biomarkers.
Do HMG-CoA reductase inhibitors improve inflammatory biomarkers in patients with cardiovascular and chronic conditions?
Do HMG-CoA reductase inhibitors improve inflammatory biomarkers in patients with cardiovascular and chronic conditions?
Statin therapy provides anti-inflammatory benefits in addition to its established lipid-lowering effects.
Statins' dual benefits support routine use in CV risk management; confirms pleiotropic effects via Level 1 evidence.
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors are commonly used drugs in the management of elevated lipid levels and cardiovascular disease. In cardiovascular diseases, among other common chronic conditions, inflammatory biomarkers are used to monitor disease progression and the risk of recurrent adverse events. We explored whether or not there was a positive effect on these biomarkers using HMG-CoA reductase inhibitors. The systematic review was conducted by gathering relevant papers mainly from three databases, identified through a generated Medical Subject Headings (MeSH) strategy. Identification of papers was subsequently followed by applying a selected inclusion and exclusion criteria to narrow the papers chosen for review. Post the application of stipulated criteria, 12 papers remained. They were subsequently assessed for risk of bias using a Cochrane risk analysis tool, identifying most as having some concerns of bias or low risk of bias. We found that HMG-CoA reductase inhibitors exhibit both a lipid-lowering effect addition to an anti-inflammatory effect.
No takes yet. Share an insight, caveat, or question.
Proute et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: